Skip to main content
. 2022 Dec 3;12:20937. doi: 10.1038/s41598-022-24732-2

Figure 2.

Figure 2

(A) The percentage of patients with potentially actionable mutations (n = 87). (B) Therapeutic options according to the mutational profile (n = 87). (C) Tumor mutation burden profiling (n = 84).